Buchang Pharma expands digital reach, health product portfolio

Shandong Buchang Pharmaceuticals announced on December 25, 2025, that its subsidiary, Shandong Buchang Zhongxinkang Medicine Technology Co., Ltd., plans to invest 1.8 million yuan to establish a new company, Buchang Internet (Hubei) Co., Ltd. (tentative name). This new entity, with a registered capital of 3 million yuan, will be 60% owned by Buchang Zhongxinkang Medicine and 40% by Hubei Hejuntengghui Trading Co., Ltd. The investment aims to enhance Buchang Zhongxinkang Medicine's operations.

Concurrently, Buchang Pharma's wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., will acquire the technical rights for six health food products, including "Yunting brand Ejiao Dihuang oral liquid." This acquisition, through a technology transfer agreement with Shaanxi Functional Food Engineering Center Co., Ltd., is for a total consideration of 7.5 million yuan (tax inclusive). The acquisition aims to enrich Buchang Pharma's product pipeline and strengthen its market competitiveness. The board approved both proposals unanimously.